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Abstract
Mu Opioid Receptor (MOR) activation by exogenous or endogenous agonists causes reduction of pain threshold 
after a noxious stimulus, relieving pain sensation. MOR is encoded by OPRM1 gene and its messenger RNA suffers 
extensible modifications by alternative splicing and single nucleotide polymorphisms (SNPs). A118G (N40D) is the 
most frequent encoding MOR SNP in humans. In this review we discuss the impact of this polymorphism at molecular, 
cellular and clinical levels. Since some SNPs are unequally distributed among human populations, we also discuss 
the utility of A118G as an ethnicity marker among worldwide human populations. As an example, we evaluate A118G 
frequency in an Argentinean human population and compare it with worldwide frequencies extracted from HapMap 
database. 
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Introduction
Morphine was isolated from opium more than 200 years ago, and 
it currently remains as the most used analgesic and reference point to 
compare new analgesic drugs [1]. Morphine belongs to a large family of 
endogenous and exogenous compounds known as opioids that bind to 
4 different seven-transmembrane G-protein coupled receptors: delta, 
kappa, orphanine and mu opioid receptor. Morphine´s highest affinity 
corresponds to the Mu Opioid Receptor (MOR) encoded by OPRM1 
gene which also is the target of endogenous opioids: enkephalins and 
β-endorphins. MOR is expressed mainly at the nervous system and its 
activation causes reduction of pain threshold after a noxious stimulus 
without anesthesia and pain relieving sensation.
There are several isoforms of MOR at the protein level generated by 
OPRM1 messenger RNA (mRNA) alternative splicing and/or by single 
nucleotide polymorphisms (SNPs). In humans, the most frequent 
encoding MOR SNP is the replacement of adenine at position 118 for a 
guanine (A118G) [2]. A118G causes the substitution of an asparagine 
by an aspartate at position 40 (MOR-N to MOR-D; N40D), which is 
placed at exon 1 in the extracellular region of the receptor before its 
first transmembrane loop [3].
Although there are many reports investigating N40D effect on 
MOR activity in pain, the impact of this SNP on the receptor function 
and its patho-physiological meaning remain elusive. At molecular 
level, we and others have reported differences in the agonist affinity 
and potency, intracellular cascades and effectors involved in MOR 
effects [4-11]. On the other hand, clinical studies have demonstrated 
changes in pain sensation and morphine requirements under different 
pain conditions [12-16]. Moreover, population studies showed a clear 
correspondence between the A118G frequency and pain parameters 
reported for human populations. Here we summarize the most relevant 
studies and discuss the cases where the results are controversial. In the 
population studies section, we also discuss the possibility that 118G 
allele may be useful to identify differences in the genetic lineage among 
human populations given its unequal worldwide distribution. In this 
regard, we present an illustrative analysis of novel data collected from 
Argentinean human population.
A118G modifies MOR activity
The amino acid substitution N40D is located at the extracellular 
N-terminal domain before the first transmembrane loop [3]. There 
are several reports describing how A118G SNP impacts on MOR 
function including changes in expression level, agonist´s affinity and 
intracellular pathways involved.
Due to the extracellular location of N40D substitution, differences 
in agonist binding and efficacy are predicted. Indeed, MOR ligand 
β-endorphin has a 3 times higher affinity for MOR-D than for MOR-N, 
while there are no changes for other opioids (enkephalins, dynorphins 
and DAMGO) between the two MOR variants [4]. In more recent 
reports, Befort et al. [5] and Beyer et al. [6] found a smaller difference: 
less than 2-fold increase in affinity. The discrepancy among these studies 
could be due to differences in the cell types used. Bond and colleagues 
found the larger difference measuring the β-endorphin binding by 
displacement of [3H] DAMGO in AV-12 cells stably transfected 
with human MOR-N and MOR-D. On the other hand, Beyer et al. 
determined the β-endorphin binding with the same method but in 
HEK293 cells stably transfected with each receptor variant, while Befort 
and colleagues measured the β-endorphin binding by displacement 
of [3H] diprenorphine in COS cells transiently transfected with each 
receptor variant.
Another predictable difference among the isoforms is a change in 
protein level and localization since the correct folding and trafficking 
to the membrane of G protein coupled receptors (GPCRs) depend on 
its extracellular domains. Zhang et al. [12] found a 200 % decrease 
of MOR-D mRNA levels as compared to MOR-N mRNA levels in 
postmortem brains samples of heterozygous humans. In the same 
study, in vitro experiments showed a similar difference in mRNA levels 
(Table 1) for CHO cells transiently transfected with human MOR-N 
and MOR-D (1.5 times lower for MOR-D40). Interestingly, a more 
prominent difference for membrane protein levels was observed: 10-
fold lower for MOR-D than for MOR-N [17] (Table 1). These data 
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suggest that the decrease of MOR protein level caused by the N40D 
polymorphism involves posttranslational mechanisms such changes in 
protein folding and/or trafficking. In this regard, the asparagine at the 
40th position has been proposed as a potential N-glycosylation site [18]. 
GPCR N-glycosylation is necessary for correct activity of chaperone 
proteins that control the folding and trafficking of GPCRs. A recent 
report showed differences in N-glycosylation levels between the human 
MOR-D and the human MOR-N variants [19] and a reduction in the 
half-life of the receptor protein by pull chase studies [19]. Thus, changes 
in N-glycosylation could explain the difference observed in expression 
levels, including the discrepancy between mRNA and protein level 
changes observed. On the other hand, other authors failed to see 
differences in the protein levels in transiently transfected COS cells [5].
Several reports also show that the N40D polymorphism modifies 
the intracellular pathways involved downstream MOR activation. 
MOR couples to Gi/o proteins and its acute activation reduces 
protein kinase A (PKA) activity and increases the Extracellular 
Receptor Kinases 1 and 2 (ERK1/2) phosphorylation [20-22]. Befort 
et al. [5] have quantified the [35S] GTPγS binding evoked by increasing 
concentrations of DAMGO in COS cells transiently transfected with 
human MOR-N and MOR-D. The apparent EC50 was similar for both 
receptor variants but the maximal response (efficacy) was higher for 
MOR-D than for MOR-N indicating that the amino acid replacement 
lead to an increase in G protein activation by the receptor (Table 1) [5]. 
In another study, Deb et al. [10] found that application of morphine 
in Neuro2A cells stably transfected with MOR-N or MOR-D caused a 
similar decrease on PKA activity and similar levels of pERK1/2 (Table 
1). Chronic exposure to MOR agonists causes receptor adaptation 
including cAMP and PKA up regulation [9,23]. In response to chronic 
treatment with morphine, Neuro2A cells expressing MOR-N showed 
high PKA activity and decreased ERK1/2 phosphorylation levels. In 
contrast, Neuro2A cells expressing MOR-D have no changes in those 
parameters, as compared to basal conditions, when exposed to chronic 
treatment with morphine indicating absence of compensatory effects 
when MOR-D is expressed [10].
The inhibition of pain sensation by MOR is, in part, due to hyper-
polarization and decreased neurotransmission mediated by increased 
potassium and reduced calcium conductances in pain pathways 
neurons [24,25]. N40D substitution modifies MOR effect on neuronal 
ion channels. MOR activates G protein activated inward rectifier 
K channels (GirK) by increasing its conductance [26]. Bond et al. 
[4] found that the activation of GirK currents was 3-fold larger for 
MOR-D than for MOR-N [4] (Table 1). Regarding calcium channels, 
MOR activation inhibits presynaptic calcium channels on nociceptive 
neurons. Nociceptors terminals are located at the dorsal horn of the 
spinal cord, where they synapse onto ascending spinal cord neurons. In 
this first synapse, stimulation of presynaptic MOR impairs excitatory 
neurotransmitter release and so, pain sensation. Some of the main 
targets of the MOR cascade are the voltage gated calcium channels 
(CaV2.2 and CaV2.1) that control synaptic vesicles release. Nociceptors 
mainly express CaV2.2, and, in particular, two mutually exclusive 
alternative splicing variant of this channel: CaV2.2e37a and CaV2.2e37b 
[27]. These two isoforms differ in 14 amino acids of the intracellular 
C terminus of the channel, and the CaV2.2e37b is ubiquitously 
expressed in the nervous system while the CaV2.2e37a is almost 
exclusively express in a subset of nociceptors [27]. Moreover, the exon 
37a containing isoform has a higher sensitivity to G protein mediated 
inhibition due to phosphorylation at tyrosine 1747 which is absent 
in exon 37b. We demonstrated that MOR-D inhibits either CaVe37a 
or CaV2.2e37b isoforms with a 4-fold smaller apparent EC50 for the 
agonist DAMGO than MOR-N [8] (Table 1). Thus, the difference in 
potency for DAMGO of MOR variants is independent of the CaV2.2 
isoform under study. Margas et al. [7] showed that native CaV currents 
were also more sensitive to inhibition by MOR-D than MOR-N. They 
studied the effect of MOR-N and MOR-D activation on CaV currents 
from superior cervical ganglia (SCG) neurons which are enriched in 
CaV2.2 channels [7]. They microinjected cDNA coding for MOR-N 
and MOR-D into SCG isolated neurons and found a higher potency of 
DAMGO on cells expressing MOR-D than MOR-N.
The studies discussed above show a higher potency for MOR-D 
than MOR-N to inhibit CaV channels. However, one study has reported 
the opposite result in humanized mice expressing human MOR-N or 
MOR-D. This study found that CaV currents from trigeminal ganglion 
neurons are inhibited at lower morphine doses when the neurons 
are injected with human MOR-D mRNA as compared with the 
inhibition observed in neurons injected with MOR-N mRNA [11]. The 
discrepancy between this report and the previously mentioned studies 
could be due to the fact that trigeminal ganglia have several CaV types 
contributing to the voltage gated calcium currents [28,29] while Lopez 
Soto et al. [8] analyzed CaV2.2 transfected in HEK293 cells and Margas 
et al. [7] studied SGC neurons where the CaV2.2 are the predominant 
voltage gated channels.
 MOR properties MOR-N vs. MOR-D Experimental conditions Ref. 
β-endorphin affinity MOR-N < MOR-D [3H]DAMGO displacement in stably transfected AV-12 cells [4] 
morphine affinity MOR-N = MOR-D 
[3H]DAMGO displacement in stably transfected AV-12 cells 
[3H]diprenorphine displacement in transiently transfected COS cells 




DAMGO affinity MOR-N = MOR-D 
[3H]DAMGO displacement in stably transfected AV-12 cells 
[3H]diprenorphine displacement in transiently transfected COS cells 




GIRK activation MOR-N < MOR-D Potassium current measured by voltage-clamp in Xenopus oocytes injected with mRNA coding for each receptor variants and GIRK. [4] 
CaV2.2 inhibition MOR-N < MOR-D Whole-cell calcium currents in transiently transfected HEK293 cells Whole-cell calcium currents in SCG neurons microinjected with each receptor variants 
[8] 
[7] 
PKA activity MOR-N = MOR-D By application of morphine in stably transfected Neuro2A cells [10] 
ERK1/2 phosphorilation MOR-N = MOR-D Western blot after application of morphine in stably transfected Neuro2A cells [10] 
Gi/o activity MOR-N < MOR-D [35S]GTPγS binding evoked by increasing concentrations of DAMGO in transiently transfected COS cells [5] 
MOR mRNA level MOR-N > MOR-D Real-time PCR in postmortem brains samples of heterozygous humans and in transiently transfected CHO cells [17] 
MOR protein level MOR-N >> MOR-D Western blot in transiently transfected CHO cells [17] 
Table 1: Summary of the N40D impact on several MOR functional properties.
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Correlation between pain sensation and analgesic 
requirements and the MOR N40D polymorphism
Studies performed in vitro have been very important to understand 
the molecular basis of the changes on MOR functionality due to 
N40D substitution. Additionally, genetically modified mouse models 
have been essential to investigate the physiological implications of 
the A118G SNP in a highly controlled experimental setting. Then, 
pain studies with human populations have well stressed the impact 
of A118G SNP on pain sensation and analgesic requirements. In this 
section we discuss the available mouse models and the more relevant 
clinical and population paper describing the impact of N40D in human 
pain treatment.
Mouse genome has an A118G equivalent polymorphism at position 
112 (A112G). This substitution exchanges an asparagine residue to an 
aspartic acid residue at position 38 (N38D), homologous to position 
40 of human MOR [30]. Mague et al. [30] taking advantage of genetic 
engineering techniques has produced knock-in mouse lines that are 
homozygous A/A or G/G at position 112 of opmr1. The authors found 
that MOR mRNA and protein levels were lower for G/G mice than for 
A/A mice in brain regions related to pain without changes in binding 
affinity for several agonists [30]. Moreover, the molecular mass of brain 
MOR was smaller in A/A mice as compared to G/G mice, presumably 
due to a decreased N-linked glycosylation in MOR-D variant. Using 
the hot plate test as a nociception assay, the authors tested the impact 
of A112G substitution in pain sensation and morphine requirements 
to relieve pain and found no differences in pain threshold between 
A/A and G/G mice. Interestingly, morphine potency was lower for 
G/G mice than A/A mice when anti-nociception was tested. Increasing 
the noxious thermal stimulus unmasks a greater baseline jumping 
behavior and lower EC50 for morphine-mediated anti-nociception in 
G/G mice compared with A/A mice [30]. As we previously mentioned, 
two humanized mouse lines also have been generated, where exon 1 
of mouse oprm1 gene was replaced by exon 1 of human OPRM1 gene, 
containing A allele or G allele exclusively [31]. Here the behavioral 
observations were also opposite to what was expected since: authors 
found a higher morphine requirement for G/G humanized mice and no 
differences when fentanyl was used as a MOR agonist. One explanation 
for these discrepancies is that human-mouse chimera receptor could 
have molecular consequences that carry artificial differences or 
similarities for polymorphism effect on MOR function. Nevertheless, 
the differences among the strategies demonstrated the complexity of 
the pain neuronal circuit’s integration.
Tolerance to pain and analgesic requirements are variable 
parameters among human individuals. This has been confirmed 
by many experimental and clinical pain trials but the mechanisms 
involved are still not fully understood. Since inter-individual pain 
sensitivity differences have a hereditable component [32], OPRM1 gen 
polymorphisms emerged as a molecular candidate.
Experimental pain studies with A118G SNP have been 
documented. This kind of studies has the advantage of producing 
pain in a measurable and controlled environment with the caveat that 
the pain does not involves a patho-physiological process. In healthy 
volunteers, one study has shown that G allele is associated with higher 
pressure pain thresholds when different pain modalities, including 
thermal, mechanical, and ischemic stimulus, were evaluated [33]. A 
sex-genotype interaction was found in terms of heat pain perception: 
G allele is associated to lower pain ratings in men and higher pain 
ratings in women. Oertel et al. [34] assessed electrically and chemically 
induced pain under serial doses of alfentanil. Tolerance to electrical 
stimuli and alfentanil doses requirements revealed a decreased opioid 
analgesia in G allele carriers as compared to A/A homozygous [34]. 
Similarly, opioids have a reduced analgesic effect in G/G homozygous 
under chemically induced pain. Romberg et al. [35] also tested 
experimental electrically induced pain under morphine-6-glucuronide 
(M6G)-induced analgesia in healthy volunteers [35]. They found a poor 
response to M6G analgesia in G allele carriers in comparison with A/A 
homozygous. Despite the caveat of the small sample number, these 
studies performed in human subjects are important to understand the 
impact of A118G in human pain.
There are numerous clinical studies assessing A118G impact in 
human pain tolerance and relief by opioids. As we presented in this 
section, available data is inconsistent maybe as a product of the diverse 
nature of the original pathological condition producing each painful 
state.
Gynecological and child birth pain are common models used to 
evaluate pain tolerance and analgesia in humans. Zhang et al. [12] 
found that G allele presence correlates with a lower threshold of pain 
tolerance to electrical stimulation in women Chinese gynecological 
patients. Moreover, G/G homozygous women needed more fentanyl 
for analgesia than heterozygous and A/A homozygous [12]. A118G 
impact on pain in women during child birth has been often reported. 
One study found a 1.5 fold lower responsiveness to opioid in A/A 
women compared to G carriers during labor analgesia [13]. Also, Sia et 
al. [14] had examined the impact of A118G in a study evaluating pain 
management in women that underwent a caesarian section surgery. 
Their results showed higher pain score and morphine requirements for 
G/G patients than A/G and A/A patients [14]. In contrast, the opposite 
result has been reported in similar postoperative pain conditions [15]. 
Thus, differences in pain threshold and opioids requirement among 
gynecological pain patients carrying G and A alleles exist but there is 
not a clear pattern among studies performed.
There are several studies testing the impact of A118G SNP in cancer 
pain. To interpret these studies is necessary to consider the source of 
pain diagnosis since pain can vary dramatically among cases. Cancer 
pain patients with an ongoing chronic morphine treatment need more 
morphine to relieve pain when they carry the G allele. In this report, an 
intriguing piece of information is that heterozygous patients feel more 
pain than A/A and G/G groups [16]. A possible explanation to this is 
that no differences in G/G individuals were detected because the sample 
size of this group was very small in this study (n = 4). Campa et al. have 
found that A allele carrying patients with cancer pain responded better 
to an opioid-based therapy than G/G or G/A patients [36].
On the other hand, Janicky et al. have inquired about A118G 
polymorphism in acute and chronic pain conditions [37]. In contrast 
to other results, they have found no significant association between 
A118G genotype and opioid dose required during or after laparoscopic 
abdominal surgery. Also they failed to detect differences in pain scores 
during the late postoperative recovery period. Moreover they analyzed 
morphine requirement in no cancer chronic pain patients. They found 
that in a subgroup with the highest opioid usage, the A/A homozygous 
required higher opioid doses than G allele carriers. Additionally, when 
they compared acute pain patient group and chronic pain patient 
group, they found that A118G SNP frequency was ~50% statistically 
lower in chronic pain group. So, the authors suggest that A118G 
SNP can be associated to a protective effect against chronic pain [37]. 
Carrying the G allele has been previously correlated with a protecting 
function against respiratory depressive effects [34], opioid dependence 
[4] and alcoholism [38,39]. In opposition, several reports failed to find 
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the same correlations [35,40-42]. On the other hand the G allele has 
been related to lower sedative effect by the synergic interaction between 
two opioid derived drugs, propofol and remifentanilfadil, used as 
anesthetics in surgeries [43].
Thus, it is clear that A118G impacts in pain sensation and opioids 
requirement since many reports showed differences among the 
genotypes. Due to the heterogeneity in the experimental conditions, it 
is difficult to arrive to a conclusive state about how this polymorphism 
modifies pain physiology in humans.
The A118G distribution across human populations
Despite the inter-individual differences in pain sensation, a 
correlation between pain and human ethnicity exists (inter-populations 
differences) [44]. Moreover, clinical studies revealed ethnic background 
as a crucial determinant in analgesic requirements in several pain states 
such as post-operative [15], chronic [45,46] and cancer pain [47,48]. 
On the other hand, the duration of opioids analgesia is different among 
patients with different ethnic backgrounds [49]. This cumulative 
information allows postulating ethnic identity as a predictor factor of 
pain sensitivity and analgesic requirements in humans [15,44].
Data supporting correlation between MOR polymorphisms and 
ethnicity in humans has been reported for several SNP [4,50,51]. In 
particular, imbalance in A118G distribution among human populations 
with different ethnic background has been reported in several studies 
[4,15,40,49,51]. Moreover, Bond et al. [4] found that the negative 
correlation between addiction to opiates and G allele frequency is 
observed only in one of the ethnic groups (Hispanic) analyzed [4]. This 
implies that the impact of A118G in human physiology could depend 
on the ethnic background.
Thus, there is a link between ethnicity and A118G distribution 
in human populations. As an illustration of this fact, we compared 
A118G SNP frequencies in human populations from the HapMap 
project database. In our analysis, we included a novel set of admixed 
European-Amerindian population samples that we collected from 
Corrientes, a north province of Argentina (CTES).
Methods
90 samples (CTES) of unrelated volunteer donors were collected 
from Corrientes City (Corrientes province, Argentina). Sampling 
consisted of blood or buccal swabs, and DNA extraction was performed 
following phenol-chloroform procedure of Sambrook et al. or Chelex 
100 [52] (BIO-RAD Laboratories, CA, USA). Each individual signed 
written consent statement form. This study is approved by the Ethics 
Committee for Biomedical Research from the Multidisciplinary 
Institute of Cell Biology (IMBICE).
A118G SNP (dbSNP Accession No. rs1799971) genotyping was 
made by PCR-RFLP as previously described by Gelernter et al. [40]. As 
control 10 samples were sequenced by Macrogen Inc. (Seoul, Korea).
Statistical analyses including deviation from Hardy-Weinberg 
equilibrium (HWE; exact test, p<0.05) and Analysis of Molecular 
Variance (AMOVA; 1023 permutation, p<0.05) were carried out with 
the software Arlequin v3.5. To test genetic structure we included 10 
International Hap Map Project population samples (www.hapmap.
org): Utah residents with Northern and Western European ancestry 
from the CEPH collection (CEU), Han Chinese in Beijing, China 
(CHB), Chinese in Metropolitan Denver, Colorado (CHD), Gujarati 
Indians in Houston, Texas (GIH), Japanese in Tokyo, Japan (JPT), 
Mexican ancestry in Los Angeles, California (MEX), Maasai in Kinyawa, 
Kenya (MKK), Tuscan in Italy (TSI), African ancestry in Southwest 
USA (ASW) and Yoruba in Ibadan, Nigeria. Luhya in Webuye, Kenya 
(LWK) population sample were excluded because A118G SNP was not 
genotyped.
Results
We evaluated if A118G SNP frequencies were distributed randomly 
within the population of samples analyzed. We first analyzed the CTES 
population samples we collected. Sample size was 90 including 42 
men (46.67%) and 48 women (53.33%). The allelic A118G frequency 
in CTES population sample was 18.89 %, and genotypic frequencies 
were A/A = 65.56%, A/G = 31.11% and G/G = 3.33%. Gender genotype 
frequencies were A/A = 59.52%, A/G = 40.48% and G/G = 0% for men, 
and A/A = 70.83%, A/G = 22.92% and G/G = 6.25% for women. CTES 
frequencies were in Hardy Weinberg equilibrium (HWE; Observed 
heterocygosis = 0.31111 and expected heterocygosis = 0.30813; Exact 
test, p = 1.000). Moreover, in the ten HapMap population samples 
analyzed, all SNP frequencies were also in HWE [53].
We then performed an AMOVA test to evaluate if A118G SNP 
distribution could reveal a genetic structure among worldwide 
populations. We tested the eleven population samples all together 
and found a population structure, with 15.68 % of variability among 
populations (Table 2, p < 0.001). To identify the most probable 
population structure we grouped them by continental genetic 
background. We defined three clusters: African (ASW, YRI and 
MKK), Asian (CHB, CHD, JPT and GIH), and European-American 
(CTES, CEU, TSI and MEX). Since American populations have an 
extensive genetic admixture pattern produced by Amerindians-
Europeans intermarriage [54,55], we decided to pool American and 
European populations. Within each cluster A118G SNP failed to detect 
population substructures (all p values > 0.09). This result validates our 
criteria to group populations with a naturally genetic background, 
at least for A118G distribution. Next, we showed that A118G SNP is 
useful to identify population structure when clustering by continental 
ethnic background. In order to distinguish the variation among the 
three defined groups, we performed an AMOVA test and found a 
20.19% of variation among groups (Table 2, p < 0.001). Accordingly, 
we also detected 79.62% of variation within populations (Table 2, p < 
0.001) without significant variation among populations within groups. 
A limitation of our study is the limited sample size. On the other hand, 
Structure tested
% of genetic variability
Within populations Among populations (within groups) Among groups
All 84.31* 15.68* -
European – American 100.25852 -0.25852 -
Asiatic 99.55105 0.44895 -
African 99.36067 0.63933 -
Three groups 79.62* 0.19 20.19*
Table 2: Analysis of Molecular Variance (AMOVA) among worldwide populations. Values indicate % of variance component in hierarchical levels in the genetic structures 
tested. *denotes statistically significant values (significance test: 1023 permutations, p<0.05).
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we could not exclude that other MOR SNPs in linkage disequilibrium 
with A118G could be counting for the genetic structure detected.
In conclusion, we were able to detect a worldwide population 
genetic structure by analyzing A118G SNP genetic variance. Moreover 
A118G frequency distributions within populations correlate with 
ethnic genetic background. This finding may be related to the shared 
genetic history by populations on the same continent and the large 
inter-group differences among the human population groups analyzed. 
Conclusion
A118G is a relevant human polymorphism that changes MOR 
physiology and impact on pain sensation and opioids requirements. 
Here, we analyzed the distribution of alleles A and G in different human 
populations including a novel Argentinean population supporting the 
notion that A118G could be useful to determine the ethnic background 
in a human population. Futures studies about this and others opioids 
system polymorphisms could contribute to develop individual and 
population targeted therapies to manage pain conditions.
Acknowledgement
We would like to thank to Dr. Mario Perello for critically reading this manuscript. 
This work was supported by the Argentinean National Council of Science (EJLS, 
CC and JR), the Council of scientific Investigation of Buenos Aires (FA) and by 
grants PICT2010-1589 and PICT2011-1816 of the National Agency of Scientific 
and technological promotion (JR).
References
1. Hamilton GR, Baskett TF (2000) In the arms of Morpheus the development of 
morphine for postoperative pain relief. Can J Anaesth 47: 367-374.
2. Levran O, Awolesi O, Linzy S, Adelson M, Kreek MJ (2011) Haplotype block 
structure of the genomic region of the mu opioid receptor gene. J Hum Genet 
56: 147-155.
3. Chen Y, Mestek A, Liu J, Yu L (1993) Molecular cloning of a rat kappa opioid 
receptor reveals sequence similarities to the mu and delta opioid receptors. 
Biochem J 295 : 625-628.
4. Bond C, LaForge KS, Tian M, Melia D, Zhang S, et al. (1998) Single-nucleotide 
polymorphism in the human mu opioid receptor gene alters beta-endorphin 
binding and activity: possible implications for opiate addiction. Proc Natl Acad 
Sci U S A 95: 9608-9613.
5. Befort K, Filliol D, Decaillot FM, Gaveriaux-Ruff C, Hoehe MR, et al. (2001) 
A single nucleotide polymorphic mutation in the human mu-opioid receptor 
severely impairs receptor signaling. J Biol Chem 276: 3130-3137.
6. Beyer A, Koch T, Schröder H, Schulz S, Höllt V (2004) Effect of the A118G 
polymorphism on binding affinity, potency and agonist-mediated endocytosis, 
desensitization, and resensitization of the human mu-opioid receptor. J 
Neurochem 89: 553-560.
7. Margas W, Zubkoff I, Schuler HG, Janicki PK, Ruiz-Velasco V (2007) 
Modulation of Ca2+ channels by heterologously expressed wild-type and 
mutant human micro-opioid receptors (hMORs) containing the A118G single-
nucleotide polymorphism. J Neurophysiol 97: 1058-1067.
8. Lopez Soto EJ, Raingo J (2012) A118G Mu Opioid Receptor polymorphism 
increases inhibitory effects on CaV2.2 channels. Neurosci Lett 523: 190-194.
9. Bohn LM, Gainetdinov RR, Lin FT, Lefkowitz RJ, Caron MG (2000) Mu-opioid 
receptor desensitization by beta-arrestin-2 determines morphine tolerance but 
not dependence. Nature 408: 720-723.
10. Deb I, Chakraborty J, Gangopadhyay PK, Choudhury SR, Das S (2010) Single-
nucleotide polymorphism (A118G) in exon 1 of OPRM1 gene causes alteration 
in downstream signaling by mu-opioid receptor and may contribute to the 
genetic risk for addiction. J Neurochem 112: 486-496.
11. Mahmoud S, Thorsell A, Sommer WH, Heilig M, Holgate JK, et al. (2011) 
Pharmacological consequence of the A118G Î¼ opioid receptor polymorphism 
on morphine- and fentanyl-mediated modulation of CaÂ²âº channels in 
humanized mouse sensory neurons. Anesthesiology 115: 1054-1062.
12. Zhang W, Chang YZ, Kan QC, Zhang LR, Lu H, et al. (2010) Association 
of human micro-opioid receptor gene polymorphism A118G with fentanyl 
analgesia consumption in Chinese gynaecological patients. Anaesthesia 65: 
130-135. 
13. Landau R, Kern C, Columb MO, Smiley RM, Blouin JL (2008) Genetic 
variability of the mu-opioid receptor influences intrathecal fentanyl analgesia 
requirements in laboring women. Pain 139: 5-14.
14. Sia AT, Lim Y, Lim EC, Goh RW, Law HY, et al. (2008) A118G single nucleotide 
polymorphism of human mu-opioid receptor gene influences pain perception 
and patient-controlled intravenous morphine consumption after intrathecal 
morphine for postcesarean analgesia. Anesthesiology 109: 520-526.
15. Tan EC, Lim EC, Teo YY, Lim Y, Law HY, et al. (2009) Ethnicity and OPRM 
variant independently predict pain perception and patient-controlled analgesia 
usage for post-operative pain. Mol Pain 5: 32.
16. Klepstad P, Rakvåg TT, Kaasa S, Holthe M, Dale O, et al. (2004) The 118 
A > G polymorphism in the human mu-opioid receptor gene may increase 
morphine requirements in patients with pain caused by malignant disease. Acta 
Anaesthesiol Scand 48: 1232-1239.
17. Zhang Y, Wang D, Johnson AD, Papp AC, Sadée W (2005) Allelic expression 
imbalance of human mu opioid receptor (OPRM1) caused by variant A118G. J 
Biol Chem 280: 32618-32624.
18. Mestek A, Hurley JH, Bye LS, Campbell AD, Chen Y, et al. (1995) The human 
mu opioid receptor: modulation of functional desensitization by calcium/
calmodulin-dependent protein kinase and protein kinase C. J Neurosci 15: 
2396-2406.
19. Huang P, Chen C, Mague SD, Blendy JA, Liu-Chen LY (2012) A common 
single nucleotide polymorphism A118G of the Î¼ opioid receptor alters its 
N-glycosylation and protein stability. Biochem J 441: 379-386.
20. Al-Hasani R, Bruchas MR (2011) Molecular mechanisms of opioid receptor-
dependent signaling and behavior. Anesthesiology 115: 1363-1381.
21. Childers SR, Fleming L, Konkoy C, Marckel D, Pacheco M, et al. (1992) Opioid 
and cannabinoid receptor inhibition of adenylyl cyclase in brain. Ann N Y Acad 
Sci 654: 33-51.
22. Chalecka-Franaszek E, Weems HB, Crowder AT, Cox BM, Cote TE (2000) 
Immunoprecipitation of high-affinity, guanine nucleotide-sensitive, solubilized 
mu-opioid receptors from rat brain: coimmunoprecipitation of the G proteins 
G(alpha o), G(alpha i1), and G(alpha i3). J Neurochem 74: 1068-1078. 
23. Terwilliger RZ, Beitner-Johnson D, Sevarino KA, Crain SM, Nestler EJ (1991) 
A general role for adaptations in G-proteins and the cyclic AMP system in 
mediating the chronic actions of morphine and cocaine on neuronal function. 
Brain Res 548: 100-110.
24. Ocaña M, Cendán CM, Cobos EJ, Entrena JM, Baeyens JM (2004) Potassium 
channels and pain: present realities and future opportunities. Eur J Pharmacol 
500: 203-219.
25. Bailey CP, Connor M (2005) Opioids: cellular mechanisms of tolerance and 
physical dependence. Curr Opin Pharmacol 5: 60-68.
26. North RA, Tokimasa T (1987) Persistent calcium-sensitive potassium current 
and the resting properties of guinea-pig myenteric neurones. J Physiol 386: 
333-353.
27. Bell TJ, Thaler C, Castiglioni AJ, Helton TD, Lipscombe D (2004) Cell-specific 
alternative splicing increases calcium channel current density in the pain 
pathway. Neuron 41: 127-138.
28. Fioretti B, Catacuzzeno L, Sforna L, Gerke-Duncan MB, van den Maagdenberg 
AM, et al. (2011) Trigeminal ganglion neuron subtype-specific alterations 
of Ca(V)2.1 calcium current and excitability in a Cacna1a mouse model of 
migraine. J Physiol 589: 5879-5895.
29. Tao J, Liu P, Xiao Z, Zhao H, Gerber BR, et al. (2012) Effects of familial 
hemiplegic migraine type 1 mutation T666M on voltage-gated calcium channel 
activities in trigeminal ganglion neurons. J Neurophysiol 107: 1666-1680.
30. Mague SD, Isiegas C, Huang P, Liu-Chen LY, Lerman C, et al. (2009) Mouse 
model of OPRM1 (A118G) polymorphism has sex-specific effects on drug-
mediated behavior. Proc Natl Acad Sci U S A 106: 10847-10852.
31. Ramchandani VA, Umhau J, Pavon FJ, Ruiz-Velasco V, Margas W, et al. 
(2011) A genetic determinant of the striatal dopamine response to alcohol in 
men. Mol Psychiatry 16: 809-817.
32. Nielsen CS, Stubhaug A, Price DD, Vassend O, Czajkowski N, et al. 
(2008) Individual differences in pain sensitivity: genetic and environmental 
contributions. Pain 136: 21-29.
Citation: Soto EJL, Agosti F, Catanesi C, Raingo J (2013) Impact of A118G Polymorphism on the Mu Opioid Receptor Function in Pain. J Pain Relief 
2: 119. doi:10.4172/2167-0846.1000119
Page 6 of 6
Volume 2 • Issue 2 • 1000119
J Pain Relief
ISSN: 2167-0846 JPAR an open access journal 
Channel Receptors in Pain Sensation
33. Fillingim RB, Kaplan L, Staud R, Ness TJ, Glover TL, et al. (2005) The A118G 
single nucleotide polymorphism of the mu-opioid receptor gene (OPRM1) is 
associated with pressure pain sensitivity in humans. J Pain 6: 159-167.
34. Oertel BG, Schmidt R, Schneider A, Geisslinger G, Lotsch J (2006) The mu-
opioid receptor gene polymorphism 118A>G depletes alfentanil-induced 
analgesia and protects against respiratory depression in homozygous carriers. 
Pharmacogenet Genomics 16: 625-636. 
35. Romberg RR, Olofsen E, Bijl H, Taschner PE, Teppema LJ, et al. (2005) 
Polymorphism of mu-opioid receptor gene (OPRM1:c.118A>G) does not 
protect against opioid-induced respiratory depression despite reduced 
analgesic response. Anesthesiology 102: 522-530. 
36. Campa D, Gioia A, Tomei A, Poli P, Barale R (2008) Association of ABCB1/
MDR1 and OPRM1 gene polymorphisms with morphine pain relief. Clin 
Pharmacol Ther 83: 559-566.
37. Janicki PK, Schuler G, Francis D, Bohr A, Gordin V, et al. (2006) A genetic 
association study of the functional A118G polymorphism of the human mu-
opioid receptor gene in patients with acute and chronic pain. Anesth Analg 
103: 1011-1017.
38. Du Y, Wan YJ (2009) The interaction of reward genes with environmental 
factors in contribution to alcoholism in mexican americans. Alcohol Clin Exp 
Res 33: 2103-2112.
39. Town T, Abdullah L, Crawford F, Schinka J, Ordorica PI, et al. (1999) Association 
of a functional mu-opioid receptor allele (+118A) with alcohol dependency. Am 
J Med Genet 88: 458-461.
40. Gelernter J, Kranzler H, Cubells J (1999) Genetics of two mu opioid receptor 
gene (OPRM1) exon I polymorphisms: population studies, and allele 
frequencies in alcohol- and drug-dependent subjects. Mol Psychiatry 4: 476-
483.
41. Kim SA, Kim JW, Song JY, Park S, Lee HJ, et al. (2004) Association of 
polymorphisms in nicotinic acetylcholine receptor alpha 4 subunit gene 
(CHRNA4), mu-opioid receptor gene (OPRM1), and ethanol-metabolizing 
enzyme genes with alcoholism in Korean patients. Alcohol 34: 115-120.
42. Bart G, Heilig M, LaForge KS, Pollak L, Leal SM, et al. (2004) Substantial 
attributable risk related to a functional mu-opioid receptor gene polymorphism 
in association with heroin addiction in central Sweden. Mol Psychiatry 9: 547-
549.
43. Borrat X, Trocóniz IF, Valencia JF, Rivadulla S, Sendino O, et al. (2013) 
Modeling the Influence of the A118G Polymorphism in the OPRM1 Gene 
and of Noxious Stimulation on the Synergistic Relation between Propofol 
and Remifentanil: Sedation and Analgesia in Endoscopic Procedures. 
Anesthesiology 118: 1395-1407.
44. Rahim-Williams FB, Riley JL 3rd, Herrera D, Campbell CM, Hastie BA, et 
al. (2007) Ethnic identity predicts experimental pain sensitivity in African 
Americans and Hispanics. Pain 129: 177-184.
45. Green CR, Baker TA, Smith EM, Sato Y (2003) The effect of race in older adults 
presenting for chronic pain management: a comparative study of black and 
white Americans. J Pain 4: 82-90.
46. McCracken LM, Matthews AK, Tang TS, Cuba SL (2001) A comparison of 
blacks and whites seeking treatment for chronic pain. Clin J Pain 17: 249-255.
47. Im EO, Chee W, Guevara E, Liu Y, Lim HJ, et al. (2007) Gender and ethnic 
differences in cancer pain experience: a multiethnic survey in the United 
States. Nurs Res 56: 296-306.
48. Jayadevappa R, Johnson JC, Chhatre S, Wein AJ, Malkowicz SB (2007) Ethnic 
variation in return to baseline values of patient-reported outcomes in older 
prostate cancer patients. Cancer 109: 2229-2238.
49. Ginosar Y, Birnbach DJ, Shirov TT, Arheart K, Caraco Y, et al. (2013) Duration 
of analgesia and pruritus following intrathecal fentanyl for labour analgesia: no 
significant effect of A118G mu-opioid receptor polymorphism, but a marked 
effect of ethnically distinct hospital populations. Br J Anaesth. 
50. Smith RJ, Doyle GA, Han AM, Crowley JJ, Oslin DW, et al. (2005) Novel exonic 
mu-opioid receptor gene (OPRM1) polymorphisms not associated with opioid 
dependence. Am J Med Genet B Neuropsychiatr Genet 133B: 105-109.
51. Hoehe MR, Köpke K, Wendel B, Rohde K, Flachmeier C, et al. (2000) Sequence 
variability and candidate gene analysis in complex disease: association of mu 
opioid receptor gene variation with substance dependence. Hum Mol Genet 9: 
2895-2908.
52. Walsh PS, Metzger DA, Higuchi R (1991) Chelex 100 as a medium for simple 
extraction of DNA for PCR-based typing from forensic material. Biotechniques 
10: 506-513. 
53. International HapMap Consortium (2003) The International HapMap Project. 
Nature 426: 789-796.
54. Corach D, Lao O, Bobillo C, van Der Gaag K, Zuniga S, et al. (2010) Inferring 
continental ancestry of argentineans from Autosomal, Y-chromosomal and 
mitochondrial DNA. Ann Hum Genet 74: 65-76.
55. Johnson NA, Coram MA, Shriver MD, Romieu I, Barsh GS, et al. (2011) 
Ancestral components of admixed genomes in a Mexican cohort. PLoS Genet 
7: e1002410.
















Citation: Soto EJL, Agosti F, Catanesi C, Raingo J (2013) Impact of A118G 
Polymorphism on the Mu Opioid Receptor Function in Pain. J Pain Relief 2: 
119. doi:10.4172/2167-0846.1000119
This	article	was	originally	published	in	a	special	issue,	Channel Receptors in Pain 
Sensation	handled	by	Editor(s).	Dr.	Helieh	Saatara	Oz,	University	of	Kentucky	
Medical	Center,	USA
